CEJEMLY Market Summary

Key Factors Driving CEJEMLY Growth

1. Expansion into multiple indications is broadening the commercial opportunity

A key growth driver is CEJEMLY's expanding label. In China, sugemalimab has secured five indications, including first-line treatment of gastric/GEJ adenocarcinoma. In Europe, CEJEMLY was approved in July 2024 for first-line metastatic NSCLC without sensitizing EGFR mutations or ALK, ROS1 or RET alterations. CStone reported that these approvals marked the drug's entry into major international markets.

The expansion beyond NSCLC is particularly important because it allows CEJEMLY to participate in additional large oncology treatment populations rather than depending on a single indication.

2. Strong long-term efficacy in metastatic NSCLC supports adoption

The Phase III GEMSTONE-302 study provides a strong clinical foundation for CEJEMLY. Sugemalimab plus platinum-based chemotherapy produced a median overall survival of 25.2 months, compared with the control arm, with a statistically significant survival benefit. Earlier analyses reported median OS of 25.4 vs. 16.9 months (HR 0.65; p=0.0008).

Updated data showed a median PFS of 9.0 vs. 4.9 months (HR 0.49), while the 4-year overall-survival rate was 32.1% vs. 17.3% for sugemalimab plus chemotherapy versus chemotherapy alone. These durable results strengthen the case for continued first-line use across both squamous and nonsquamous metastatic NSCLC.

3. Gastric/GEJ cancer provides an important second growth engine

CEJEMLY's development has expanded into advanced or metastatic gastric/GEJ adenocarcinoma, particularly patients with PD-L1 CPS ≥5. The Phase III GEMSTONE-303 study was a randomized, double-blind, placebo-controlled trial conducted at 54 sites in China and demonstrated statistically significant improvements in both PFS and OS when sugemalimab was added to CAPOX chemotherapy.

The indication received Chinese approval in 2024, providing CEJEMLY with another first-line solid-tumor opportunity. CStone's subsequent publication of GEMSTONE-303 results in JAMA further strengthens the evidence base and physician awareness.

4. International expansion could materially increase future revenue

CStone has moved CEJEMLY beyond China through regulatory approvals and partnerships. The European Commission approved CEJEMLY in 2024 for first-line metastatic NSCLC, making it the first China-developed anti-PD-L1 antibody to reach the European market in this setting.

CStone reported in 2026 that partnerships had extended sugemalimab's commercial reach to more than 60 countries and regions worldwide. Such geographic expansion provides an important long-term growth lever as launches progress and reimbursement/access are established in additional markets.

5. Guideline recognition can accelerate physician adoption

CEJEMLY's inclusion in treatment guidelines is another positive commercial factor. In February 2025, sugemalimab was included in the ESMO NSCLC Living Guideline as a Level I,A first-line combination therapy for both non-oncogene-addicted metastatic squamous and nonsquamous NSCLC.

Guideline recognition is particularly valuable for an internationally expanding product because it can improve physician familiarity, support treatment positioning and facilitate reimbursement discussions in markets where the product is newly launched.

CEJEMLY Recent Developments

In February 2025, CStone Pharmaceuticals announced that its key product, CEJEMLY (sugemalimab), had been included in the European Society for Medical Oncology (ESMO) Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer (NSCLC) Living Guideline. Sugemalimab is recommended as a first-line combination therapy for both squamous and non-squamous NSCLC, with substantial clinical benefits. This is a significant milestone in sugemalimab's global journey and provides critical support for our efforts to expand market access, enter the markets, and reach patients.

“CEJEMLY Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of CEJEMLY for approved indication like Adenocarcinoma, Extranodal NK-T-cell lymphoma, Non-small cell lung cancer, and Squamous cell cancer; as well as potential indication like T-cell lymphoma, Hodgkin’s disease, Liver cancer, and Solid tumours in the 7MM. A detailed picture of CEJEMLY’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the CEJEMLY for approved and potential indications. The CEJEMLY market report provides insights about CEJEMLY’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current CEJEMLY performance, future market assessments inclusive of the CEJEMLY market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of CEJEMLY sales forecasts, along with factors driving its market.

CEJEMLY Drug Summary

CEJEMLY is a fully human IgG4 monoclonal antibody targeting programmed death-ligand 1 (PD-L1), developed by CStone Pharmaceuticals as an immune checkpoint inhibitor for the treatment of non-small cell lung cancer (NSCLC). Sugemalimab binds to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interaction with PD-1 and CD80 and thereby relieving PD-L1-mediated immune suppression to restore T-cell-mediated antitumor activity. CEJEMLY is administered intravenously, with the European-approved formulation supplied as a 600 mg/20 mL concentrate for solution for infusion. It is indicated in combination with platinum-based chemotherapy for the first-line treatment of adults with metastatic NSCLC without sensitizing EGFR mutations or ALK, ROS1, or RET genomic tumor aberrations; it is also indicated as monotherapy for unresectable stage III NSCLC without sensitizing EGFR mutations or ALK or ROS1 genomic tumor aberrations in adults whose tumors express PD-L1 on at least 1% of tumor cells and whose disease has not progressed following platinum-based chemoradiotherapy. The report provides CEJEMLY’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the CEJEMLY Market Report

The report provides insights into:

• A comprehensive product overview including the CEJEMLY MoA, description, dosage and administration, research and development activities in approved indications like Adenocarcinoma, Extranodal NK-T-cell lymphoma, Non-small cell lung cancer, and Squamous cell cancer; as well as potential indication like T-cell lymphoma, Hodgkin’s disease, Liver cancer, and Solid tumours.
• Elaborated details on CEJEMLY regulatory milestones and other development activities have been provided in CEJEMLY market report.
• The report also highlights CEJEMLY‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The CEJEMLY market report also covers the patents information, generic entry and impact on cost cut.
• The CEJEMLY market report contains current and forecasted CEJEMLY sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The CEJEMLY market report also features the SWOT analysis with analyst views for CEJEMLY in approved and potential indications.

Methodology

The CEJEMLY market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CEJEMLY Analytical Perspective by DelveInsight

• In-depth CEJEMLY Market Assessment

This CEJEMLY sales market forecast report provides a detailed market assessment of CEJEMLY for approved indication like Adenocarcinoma, Extranodal NK-T-cell lymphoma, Non-small cell lung cancer, and Squamous cell cancer; as well as potential indication like T-cell lymphoma, Hodgkin’s disease, Liver cancer, and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted CEJEMLY sales data uptil 2034.

• CEJEMLY Clinical Assessment

The CEJEMLY market report provides the clinical trials information of CEJEMLY for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

CEJEMLY Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

CEJEMLY Market Potential & Revenue Forecast

• Projected market size for the CEJEMLY and its key indications
• Estimated CEJEMLY sales potential (CEJEMLY peak sales forecasts)
• CEJEMLY Pricing strategies and reimbursement landscape

CEJEMLY Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• CEJEMLY Market positioning compared to existing treatments
• CEJEMLY Strengths & weaknesses relative to competitors

CEJEMLY Regulatory & Commercial Milestones

• CEJEMLY Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

CEJEMLY Clinical Differentiation

• CEJEMLY Efficacy & safety advantages over existing drugs
• CEJEMLY Unique selling points

CEJEMLY Market Report Highlights

• In the coming years, the CEJEMLY market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The CEJEMLY companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CEJEMLY’s dominance.
• Other emerging products for Adenocarcinoma, Extranodal NK-T-cell lymphoma, Non-small cell lung cancer, and Squamous cell cancer; as well as potential indication like T-cell lymphoma, Hodgkin’s disease, Liver cancer, and Solid tumours are expected to give tough market competition to CEJEMLY and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CEJEMLY in approved and potential indications.
• Analyse CEJEMLY cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted CEJEMLY sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of CEJEMLY in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of CEJEMLY? How strong is CEJEMLY’s clinical and commercial performance?
• What is CEJEMLY’s clinical trial status in each individual indications such as Adenocarcinoma, Extranodal NK-T-cell lymphoma, Non-small cell lung cancer, and Squamous cell cancer; as well as potential indication like T-cell lymphoma, Hodgkin’s disease, Liver cancer, and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CEJEMLY Manufacturers?
• What are the key designations that have been granted to CEJEMLY for approved and potential indications? How are they going to impact CEJEMLY’s penetration in various geographies?
• What is the current and forecasted CEJEMLY market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of CEJEMLY in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to CEJEMLY for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is CEJEMLY? What is the duration of therapy and what are the geographical variations in cost per patient?